Clinical Trial Update: JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL) [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 clinical trial of JY231 injection for B-cell acute lymphoblastic leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• JY231 Injection

Snippet

Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL) | EARLY_Phase 1 | Status: RECRUITING